METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS

METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS

Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SHANE GUANG-TZUU, TSAI PEIN, DIN CHUEN-LIN, CHEN CHIEN-FEN, TSAI HUI-LING
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SHANE GUANG-TZUU
TSAI PEIN
DIN CHUEN-LIN
CHEN CHIEN-FEN
TSAI HUI-LING
description Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2011171302A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2011171302A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2011171302A13</originalsourceid><addsrcrecordid>eNqNzDELwjAQBeAuDqL-hwPnQlMH59i7poE2B5dEx1IkTqKF-iv81bYgzk4PHt976-zdUWgYoWaBIKSDdQYcRWEkQ45kbs4EaD0Lkni42NAAi24B2WtDy7KL7czYQcUuaOuWjxPPznYdodWBcqGWtCfQDsFHvyjCX4sSjd9mq9twn9Lum5tsX1OomjyNzz5N43BNj_Tqoy8LpdRRHYpSq8N_6gMfgUAx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS</title><source>esp@cenet</source><creator>SHANE GUANG-TZUU ; TSAI PEIN ; DIN CHUEN-LIN ; CHEN CHIEN-FEN ; TSAI HUI-LING</creator><creatorcontrib>SHANE GUANG-TZUU ; TSAI PEIN ; DIN CHUEN-LIN ; CHEN CHIEN-FEN ; TSAI HUI-LING</creatorcontrib><description>Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20110714&amp;DB=EPODOC&amp;CC=US&amp;NR=2011171302A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20110714&amp;DB=EPODOC&amp;CC=US&amp;NR=2011171302A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHANE GUANG-TZUU</creatorcontrib><creatorcontrib>TSAI PEIN</creatorcontrib><creatorcontrib>DIN CHUEN-LIN</creatorcontrib><creatorcontrib>CHEN CHIEN-FEN</creatorcontrib><creatorcontrib>TSAI HUI-LING</creatorcontrib><title>METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS</title><description>Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzDELwjAQBeAuDqL-hwPnQlMH59i7poE2B5dEx1IkTqKF-iv81bYgzk4PHt976-zdUWgYoWaBIKSDdQYcRWEkQ45kbs4EaD0Lkni42NAAi24B2WtDy7KL7czYQcUuaOuWjxPPznYdodWBcqGWtCfQDsFHvyjCX4sSjd9mq9twn9Lum5tsX1OomjyNzz5N43BNj_Tqoy8LpdRRHYpSq8N_6gMfgUAx</recordid><startdate>20110714</startdate><enddate>20110714</enddate><creator>SHANE GUANG-TZUU</creator><creator>TSAI PEIN</creator><creator>DIN CHUEN-LIN</creator><creator>CHEN CHIEN-FEN</creator><creator>TSAI HUI-LING</creator><scope>EVB</scope></search><sort><creationdate>20110714</creationdate><title>METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS</title><author>SHANE GUANG-TZUU ; TSAI PEIN ; DIN CHUEN-LIN ; CHEN CHIEN-FEN ; TSAI HUI-LING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2011171302A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2011</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SHANE GUANG-TZUU</creatorcontrib><creatorcontrib>TSAI PEIN</creatorcontrib><creatorcontrib>DIN CHUEN-LIN</creatorcontrib><creatorcontrib>CHEN CHIEN-FEN</creatorcontrib><creatorcontrib>TSAI HUI-LING</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHANE GUANG-TZUU</au><au>TSAI PEIN</au><au>DIN CHUEN-LIN</au><au>CHEN CHIEN-FEN</au><au>TSAI HUI-LING</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS</title><date>2011-07-14</date><risdate>2011</risdate><abstract>Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2011171302A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T20%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHANE%20GUANG-TZUU&rft.date=2011-07-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2011171302A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true